Tuesday, November 24, 2009, 5:51AM AEST - The Australian Stockmarket opens in 4 hours and 9 minutes.
To create a watchlist or portfolio of shares, Register

Shire plc (SHPGY)

5:35AM AEST: 57.14 USD  Up 0.71 (1.26%)  
 MORE ON SHPGY 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Shire plc (NasdaqNM:SHPGY) Delayed quote dataEdit
Last Trade:57.14 USD
Trade Time: 5:35AM AEST
Change:Up 0.71 (1.26%)
Prev Close:56.43
Open:58.12
Bid:57.13 x 100
Ask:57.15 x 300
1y Target Est:58.37
Day's Range:56.93 - 58.56
52wk Range:31.66 - 60.32
Volume:650,924
Avg Vol (3m):735,956
Market Cap:N/A
P/E (ttm):N/A
EPS (ttm):N/A
Div & Yield:0.30 (0.53%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add SHPGY to Portfolio   Download Data

 HEADLINES 
This Stock Is a Train Wreck
at Motley Fool (Fri, Nov 20)
Genzyme's Problems Continue
Zacks.com (Fri, Nov 20)
Lumizyme Rejected Again: Downgrading Genzyme Recommendation from Buy to Hold
at Seeking Alpha (Wed, Nov 18)
Zacks Bull and Bear of the Day Highlights: Sealed Air Corporation, Hologic, Inc., Genzyme Corp., Shire plc and Protalix BioTherapeutics Inc.
Zacks.com (Tue, Nov 17)
Contamination Issues Haunt Genzyme
Zacks.com (Tue, Nov 17)
Shire Plc downgraded by Caris & Company
Briefing.com (Tue, Nov 17)
Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
PR Newswire (Tue, Nov 17)
Before the Bell: Cisco, Shire, EADS in focus Monday
at MarketWatch (Tue, Nov 17)
Shire downgraded to hold at Lazard
at MarketWatch (Tue, Nov 17)
Developments for Parkinson's Disease Ignite Investor Enthusiasm
at Seeking Alpha (Mon, Nov 16)
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
EDGAR Online (Sat, Nov 14)
Shire Reports Findings From an Analysis Examining Emotional Lability in Children With ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
PR Newswire (Fri, Nov 13)
SHIRE PLC Financials
EDGAR Online Financials (Thu, Nov 12)
Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
PR Newswire (Thu, Nov 12)
Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
PR Newswire (Tue, Nov 10)
More Headlines for SHPGY...

 ANALYST 
EPS Est (next year) (Dec-09) :2.95
EPS Est (in 2 years) (Dec-10) :3.24
Avg Rec (current)*:1.9
PEG Ratio:2.11
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
No business summary available for SHPGY.


Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices